A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Emavusertib (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms LUCAS
- 15 Aug 2024 Status changed from suspended to completed.
- 24 Mar 2024 Status changed from recruiting to suspended.
- 08 Oct 2021 Status changed from not yet recruiting to recruiting.